Dry powder formulations for inhalation o
โ
Darragh Murnane; Gary P. Martin; Christopher Marriott
๐
Article
๐
2009
๐
John Wiley and Sons
๐
English
โ 307 KB
Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous cryst